Milo Biotechnology

Novartis AG said when it disclosed that preclinical safety data for Zolgensma were manipulated in the biologic license application for the gene therapy that the company would be "exiting" employees i

Pfizer Inc. ’s R&D strategy in Duchenne muscular dystrophy now will focus primarily on gene therapy candidates, as the pharma announced Aug. 30 that it is shelving domagrozumab due to its failure to m

[Abionic SA] c/o EPFL-STI-LOB-BM4247 Station 17 1015 Lausanne, Switzerland Phone: +41 79 753 57 66 Email: info@abionic.com Web Site: www.abionic.com Management: Nicolas Durand, PhD, CEO; Iwan

[Abionic SA] c/o EPFL-STI-LOB-BM4247 Station 17 1015 Lausanne, Switzerland Phone: +41 79 753 57 66 Email: info@abionic.com Web Site: www.abionic.com Abionic has developed a fast, low-cost alt